股价表现 - Adma Biologics (ADMA) 最近的股价表现优于标普500指数和纳斯达克指数[1] - Adma Biologics 过去一个月的股价上涨0.16%，领先医疗行业和标普500指数[2] 财务预测 - Adma Biologics 即将发布的财报显示预计每股收益将大幅增长，营收也有望增长[3] - Adma Biologics 的前瞻市盈率为20.9，低于同行业的22.02[7] 分析师建议 - 分析师对 Adma Biologics 的预期变化会直接影响股价，Zacks Rank 模型显示公司目前为强烈买入[4] 行业排名 - 医疗 - 生物医学和遗传学行业在所有250+行业中排名前34%[8] - Zacks Industry Rank 显示排名前50%的行业胜过后50%的行业[9] 建议 - 建议关注 Zacks.com 来跟踪这些影响股价的指标[10]

In the latest trading session, Adma Biologics (ADMA) closed at $6.04, marking a -1.95% move from the previous day. The stock's change was less than the S&P 500's daily loss of 0.58%. On the other hand, the Dow registered a loss of 0.12%, and the technology-centric Nasdaq decreased by 1.15%.Prior to today's trading, shares of the infectious disease drug developer had lost 0.48% over the past month. This has was narrower than the Medical sector's loss of 6.07% and the S&P 500's loss of 1.09% in that time.The ...

U.S. stock markets maintained their northbound journey in the first quarter of 2024 after an impressive 2023. In first-quarter 2024, the S&P 500 rallied 10.2%, marking its best first-quarter performance since 2019. The Dow surged 5.6%, reflecting its strongest first-quarter performance since 2021. The tech-heavy Nasdaq Composite appreciated 9.1% in the same quarter.However, volatility returned to Wall Street in the first week of April. The Dow slid 2.3%, posting its worst weekly performance in 2024. The S&P ...

ADMA生物制品公司产品推出 - ADMA生物制品公司市场推出了三种血浆衍生生物制品，用于治疗免疫缺陷和预防某些传染病[1] - FDA批准了ADMA生物制品公司Asceniv和Bivigam的补充生物制品许可申请，扩大了存储条件，预计将提高这些免疫球蛋白产品的销售额[3][4] ADMA生物制品公司收入指导提高 - ADMA生物制品公司由于2023年商业产品的强劲销售表现，提高了2024年和2025年的收入指导[5] S. pneumonia高免疫球蛋白管线项目 - 公司计划在2024年晚些时候推进其S. pneumonia高免疫球蛋白管线项目的前临床工作，该项目有望在成功开发和批准后产生每年3亿至5亿美元的峰值收入[7]

Adma Biologics (ADMA) closed the latest trading day at $6.54, indicating a -0.91% change from the previous session's end. The stock trailed the S&P 500, which registered a daily loss of 0.2%. Elsewhere, the Dow lost 0.6%, while the tech-heavy Nasdaq added 0.11%.The the stock of infectious disease drug developer has risen by 19.57% in the past month, leading the Medical sector's gain of 2.21% and the S&P 500's gain of 3.32%.The investment community will be closely monitoring the performance of Adma Biologics ...

股价表现 - Adma Biologics (ADMA) 最新收盘价为$6.29，较前一日上涨了+1.62% [1] - Adma Biologics股价在过去一个月内上涨了17.68%，超过了医疗行业0.88%和标普500指数5.34%的涨幅 [2] 财报预测 - 分析师和投资者将密切关注Adma Biologics即将公布的财报。预计公司将发布每股收益为$0.05，较去年同期增长266.67%；同时，最新的共识预测预计营收为$76.7百万美元，较去年同期增长34.77% [3] 公司评级 - 公司的Zacks Rank为1（强烈买入），过去30天Zacks共识每股收益预测增长了32.84% [6]

U.S. stock markets have been maintaining their northbound journey in the first quarter of 2024 after an impressive 2023. Year to date, the three major stock indexes — the Dow, the S&P 500 and the Nasdaq Composite — have rallied 4.8%, 10.2% and 10.9%, respectively.On Mar 20, after its FOMC meeting, the Fed kept the benchmark lending rate constant in the range of 5.25-5.5%. However, the Fed’s latest “dot-plot” (a closely watched matrix of anonymous projections from the 19 officials who comprise the FOMC) show ...

When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a trend to profit from it is easier said than done.The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the st ...

Adma Biologics (ADMA) closed the last trading session at $5.99, gaining 13.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $8 indicates a 33.6% upside potential.The mean estimate comprises four short-term price targets with a standard deviation of $1.63. While the lowest estimate of $6 indicates a 0.2% increase from the current price level, the most optimistic analyst expects th ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?Let's take a look at what these Wall Street heavyweights have to say about Adma Biologics (ADMA) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.Adma Biologics currently has an aver ...